a HEp-2 cell substrate is that of DFS interphase nuclei, with strongly fluorescent mitotic chromosomes-ICAP pattern AC-2. Patients with a DFS70-ANA are reported to rarely develop systemic autoimmune rheumatic disease (SARD), especially in the absence of significant clinical findings or other ENA specificities, prompting suggestion that an isolated DFS70-ANA is an exclusionary finding for SARD. Methods: ANAs were tested using Euroimmun HEp-2 slides. DFS ANAs were reported as possibly DFS70-related, with ENA follow-up testing recommended. ENA profiling used the Euroimmun Immunoblot ANA Profile 3 plus DFS70 kit-15 separate ENA specificities. Results: Of 6,511 samples tested for ANA in 2016, 1,758 (27%) had a DFS ANA pattern. ENA profiling of these 1,758 DFS ANAs showed the following: 720 (41%) showed positivity for anti-DFS70, 526 (73%) of DFS70 ENAs showed isolated anti-DFS70 specificity, 194 (27%) of DFS70 ENAs showed additional ENA specificities, 1,037 (59%) of DFS ANAs were negative for anti-DFS70 specificity. Rheumatologist chart reviews showed no patient with an isolated DFS70-ANA to have an ANA-related SARD, while DFS70-ANA patients showing other ENA specificities showed a variety of SARD appropriate to the specificity and strength of the other ENAs. Conclusion: Recognition of a DFS ANA pattern, followed by confirmation of DFS70 specificity, should be a routine ANA testing service. Recognition of an isolated DFS70-ANA enables reassurance of patients, who may be over-diagnosed or referred for more extensive testing for SARD. Clinical symptoms and/or significant elevations of coexistent ENAs warrant close clinical follow-up.
a HEp-2 cell substrate is that of DFS interphase nuclei, with strongly fluorescent mitotic chromosomes-ICAP pattern AC-2. Patients with a DFS70-ANA are reported to rarely develop systemic autoimmune rheumatic disease (SARD), especially in the absence of significant clinical findings or other ENA specificities, prompting suggestion that an isolated DFS70-ANA is an exclusionary finding for SARD. Methods: ANAs were tested using Euroimmun HEp-2 slides. DFS ANAs were reported as possibly DFS70-related, with ENA follow-up testing recommended. ENA profiling used the Euroimmun Immunoblot ANA Profile 3 plus DFS70 kit-15 separate ENA specificities. Results: Of 6,511 samples tested for ANA in 2016, 1,758 (27%) had a DFS ANA pattern. ENA profiling of these 1,758 DFS ANAs showed the following: 720 (41%) showed positivity for anti-DFS70, 526 (73%) of DFS70 ENAs showed isolated anti-DFS70 specificity, 194 (27%) of DFS70 ENAs showed additional ENA specificities, 1,037 (59%) of DFS ANAs were negative for anti-DFS70 specificity. Rheumatologist chart reviews showed no patient with an isolated DFS70-ANA to have an ANA-related SARD, while DFS70-ANA patients showing other ENA specificities showed a variety of SARD appropriate to the specificity and strength of the other ENAs. Conclusion: Recognition of a DFS ANA pattern, followed by confirmation of DFS70 specificity, should be a routine ANA testing service. Recognition of an isolated DFS70-ANA enables reassurance of patients, who may be over-diagnosed or referred for more extensive testing for SARD. Clinical symptoms and/or significant elevations of coexistent ENAs warrant close clinical follow-up.
Neuroendocrine Carcinoma of the Breast: An Underdiagnosed Neoplasm With Enhanced Metastatic Potential
Lubna Alattia, MD, Kurt Knowles, MD, Mingxia Shi, MD, Maria-Magdalena Georgescu, MD, PhD; LSU Health-Shreveport, Shreveport, LA Background: Primary neuroendocrine carcinoma of the breast (NECB) is a rare entity of breast cancer; it shows a neuroendocrine differentiation in at least 50% of tumor cells with positive immunoreactivity to neuroendocrine markers. Clinical features and morphology are not always enough to enable distinction of NECB from other subtypes of breast cancer. Case Presentation: We report three patients who presented with primary breast masses and subsequent skull and spinal masses. The patient ages were 62, 61 and 44 years old, and the metastatic mass sizes were 4.3, 4, and 2 cm, respectively. The histopathologic analysis showed metastatic breast carcinoma to the spine in the two older patients and a benign skull vascular lesion in the younger patient. Results: The first patient was diagnosed with thoracic spinal cord metastatic breast cancer as the first manifestation of her disease. Subsequent breast lumpectomy revealed a high-grade invasive ductal carcinoma. The second patient had an estrogen receptor (ER)-positive breast no special type (ductal) carcinoma refractory to conventional therapy for four years before developing a spinal mass. This mass showed focal rosette formation and investigation revealed positivity for neuroendocrine markers. This new diagnosis of neuroendocrine carcinoma prompted reanalysis with neuroendocrine markers of the first patient's tumors, as well as of that from a third patient, who presented with a breast mass and a skull lesion. Although the skull lesion was not a metastasis, all of these patients' ER-positive breast carcinomas were confirmed to be neuroendocrine breast tumors. Conclusion: Increased awareness of the existence of this highly metastatic breast tumor entity that may be resistant to conventional therapy will reduce its underdiagnosis and allow better clinical management of this disease. Schleswig-Holstein, Campus Lübeck, Lübeck, Germany Objectives: The incidence of carcinomas of the esophagogastric junction has increased over the last decades. Neoadjuvant chemotherapy is regularly implemented, but patients' response varies greatly, some cases showing no therapeutic effect, being deemed chemoresistant. Small, noncoding RNAs-miRNAs-have evolved as key players in biological processes, including malignant diseases, promoting tumor growth and expansion via cell dissociation, invasion, migration, and proliferation. Additionally, specific miRNAs (hsa-miR-21, hsa-miR-181b, hsamiR-221/222) have been implicated in the development of chemoresistance through evasion of apoptosis, cell cycle alterations, and drug target modification. As data concerning chemoresistance in carcinomas of the esophagogastric junction are still scarce, our study aimed to further contribute to the knowledge for this entity. Methods: A retrospective study of 33 patients receiving neoadjuvant chemotherapy was performed. Histologic tumor regression was evaluated using resection specimens,
Increased Expression of hsa-let-7f-5p, hsa-miR-221-3p and hsa-miR-31-5p Correlates With Chemoresistance in Carcinoma of the Esophagogastric Junction

